Inactivation and removal of human immunodeficiency virus in monoclonal purified antihemophilic factor (human) (Hemofil M).
Cold supernatant which was prepared from factor VIII:C containing cryoprecipitate was seeded with HIV-1, then treated with a mixture of tri (n-butyl) phosphate (TNBP) and triton X-100. A greater than 10(11)-fold reduction of HIV-1 infectivity was observed. In a separate experiment, cold supernatant which had been seeded with HIV-1 was chromatographed on an immunoaffinity column, resulting in a 10(4)-fold reduction of infectivity. None of the 17 patients treated with the purified product and followed for at least three months has shown serologic evidence of HIV-1 or other viral infections.
Piszkiewicz
D
D
Hyland Division, Baxter Healthcare Corporation, Duarte, California 91010.
Sun
C S
CS
Tondreau
S C
SC
D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D000911:Antibodies, Monoclonal / Q000276:immunology*; D002478:Cells, Cultured; D002846:Chromatography, Affinity; D019855:Ethylene Glycol; D005026:Ethylene Glycols / Q000494:pharmacology*; D005169:Factor VIII / Q000302:isolation & purification* / Q000627:therapeutic use; D006678:HIV / Q000187:drug effects* / Q000472:pathogenicity; D015483:HIV Antibodies / Q000276:immunology*; D015488:HIV Antigens / Q000032:analysis; D006467:Hemophilia A / Q000628:therapy; D006801:Humans; D017830:Octoxynol; D010755:Organophosphates / Q000494:pharmacology*; D009943:Organophosphorus Compounds / Q000494:pharmacology*; D011092:Polyethylene Glycols / Q000494:pharmacology*; D014774:Virulence / Q000187:drug effects; D014779:Virus Replication
D000911:Antibodies, Monoclonal; D005026:Ethylene Glycols; D015483:HIV Antibodies; D015488:HIV Antigens; D010755:Organophosphates; D009943:Organophosphorus Compounds; D011092:Polyethylene Glycols; D005169:Factor VIII; D017830:Octoxynol; C009524:tributyl phosphate; D019855:Ethylene Glycol